[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Copenhagen University Hospital, Rigshospitalet\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,78,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100659047","phase-2-paediatric-sarcoma-hybrid-imaging--fapi---raising-the-diagnostic-standard-for-paediatric-sarcoma-patients-combining-novel-radiotracer-fapi-and-whole-body-petmri-100659047",false,"NCT07861217","Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET\u002FMRI","Paediatric Sarcoma, Hybrid Imaging & FAPI - An Investigator-initiated, Non-inferiority, Single-group, Phase II Clinical Trial, Evaluating FAPI WB PET\u002FMRI at Primary Staging, Treatment Control and Relapse in Paediatric Sarcoma - The PsiFI Trial","PsiFI","Inclusion Criteria:\n\n* \\\u003C18 years old.\n* Referred to the Recruiting Department for evaluation of any type of sarcoma.\n* The patient and\u002For parent(s) must be able to read and understand the Participant Information Sheet (PIS) in Danish and\u002For English and provide innformed consent by signing the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Considered unable by the referring department to comply with the study imaging procedures without sedation.\n* Severe claustrophobia or any contraindication indentified through the MRI safety screening questionnaire.\n* History of an allergic reaction due to compounds with a chemical composition similar to that of \\[68Ga\\]FAPI-46.","ALL","17 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate \\[68Ga\\]FAPI-46 whole-body PET\u002FMRI as a diagnostic tool to improve tumour lesion examination at primary staging, during treatment control and at relapse in paediatric sarcoma patients.\n\nThe main questions the trial aim to answer are:\n\n* Is \\[68Ga\\]FAPI-46 whole-body PET\u002FMRI better at detecting malignancy in paediatric sarcoma patients compared to current standard of care imaging modalities?\n* Is the overall diagnostic performance of \\[68Ga\\]FAPI-46 whole-body PET\u002FMRI feasible to implement in clinical practice?\n\nThe intervention of \\[68Ga\\]FAPI-46 will be compared to current standard of care imaging modalities. All participants will receive their standard of care imaging protocol as rutinely scheduled, which includes:\n\n* A localized MRI scan of the tumour region and\n* An \\[18F\\]FDG whole-body PET\u002FCT scan\n\nIn addition to the standard of care imaging protocol, all patients will receive the following experimental scans:\n\n* An \\[18F\\]FDG whole-body PET\u002FMRI\n* A \\[68Ga\\]FAPI-46 whole-body PET\u002FMRI\n* A \\[68Ga\\]FAPI-46 whole-body PET\u002FCT\n\nAll patients and legal guardians will fill out questionnaires on their experiences. Patients may undergo the entire trial imaging procedures, including the standard of care imaging protocol and the experimental scans, a maximum of five times.",[27],"Sarcoma",[29,30,31,32],"pediatric sarcoma","WB PET\u002FMRI","FAPI","WB PET\u002FCT","NOT_YET_RECRUITING","2026-10-02",{"date":36,"type":37},"2026-10-06","ACTUAL",{"date":39,"type":21},"2026-12",{"date":41,"type":21},"2029-06",{"name":43,"class":44},"Copenhagen University Hospital, Rigshospitalet","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100626955","the-per-procedural-antibiotic-prophylaxis-in-patients-undergoing-transcatheter-aortic-valve-implantation-trial-100626955","NCT07442357","The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial","PAPPI","Inclusion Criteria:\n\n* All patients \\> 18 years of age undergoing TAVI at sites in Denmark\n\nExclusion Criteria:\n\n* Patients who do not want to participate and have chosen to \"opt-out\" of the trial","18 Years",{"count":55,"type":21},1986,[57],"NA","The study is a prospective, crossover, cluster randomized trial in patients undergoing transcatheter aortic valve implantation (TAVI). The study tests whether cephalosporin plus beta-lactam antibiotic with spectrum for Enterococcus faecalis as per procedural prophylaxis is superior to cephalosporin alone in reducing the composite outcome of bacteremia or death at 6 months post-TAVI.",[60],"Aortic Valve Stenosis",[60,62,63,64,65,66,67,68],"Aortic Valve Replacement","Transcatheter Aortic Valve Replacement","Aortic Valve","Cephalosporin","Ampicllin","Bacteremia","Per Procedure Prophylaxis","RECRUITING",{"date":71,"type":37},"2026-10-05",{"date":73,"type":37},"2026-10-01",{"date":75,"type":21},"2030-03-31",{"name":43,"class":44},5,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":45},"100625911","pulmonary-and-total-blood-volume-in-copd-100625911","NCT07428785","Pulmonary and Total Blood Volume in COPD","Pulmonary and Total Blood Volume in COPD: A Prosoective Matched Comparative Study","COPD-TBV","Inclusion Criteria:\n\n* Inclusion criteria -patients\n\n  * Men and women\n  * 45-80 years\n  * COPD (GOLD stage I to III)\n  * Resting arterial oxygenation \\> 90% Inclusion criteria - controls\n  * Men and women\n  * 45-80 years\n  * Normal FEV1, FVC, FEV1\u002FFVC, and single-breath diffusion capacity\n  * Same sex, age (± 3 years) and height (± 5 cm) as an included COPD patient\n  * Low- to moderate activity level defined as \\\u003C 1,5 hours of structured physical activity pr. week at moderate intensity and cycling \\\u003C 30 minutes\u002F5km pr. day at moderate intensity (moderate intensity = out of breath but able to speak)\n\nExclusion Criteria:\n\nExclusion criteria - patients\n\n* Symptoms of ischaemic heart disease\n* Known heart failure\n* Previous severe or current COVID-19\n* Claudication\n* Symptoms of disease within 2 weeks prior to the study\n* Participation in pulmonary rehabilitation within 6 months\n* Known malignant disease\n* Pregnancy\n* Unstable cardiac arrhythmic disease\n* Renal or liver dysfunction\n\nExclusion criteria - controls\n\n* Known chronic lung disease\n* Known ischaemic heart disease\n* Known heart failure\n* Previous severe or current COVID-19\n* Symptoms of disease within 2 weeks prior to the study\n* Known malignant disease\n* Claudication\n* Pregnancy\n* Unstable cardiac arrhythmic disease\n* Renal or liver dysfunction",true,"45 Years","80 Years",{"count":90,"type":21},32,"OBSERVATIONAL","Background Patients with chronic obstructive lung disease (COPD) suffer from a progressive loss of lung function that leads to poor quality of life, and often invalidity and early death. This is markedly affected by a reduced exercise capacity and dyspnoea, but the underlying mechanisms are unknown. In the present study, we aim to investigate whether this may involve a reduced pulmonary blood volume secondarily to a reduced total blood volume.\n\nMethods Design: Prospective matched comparative study Intervention: None\n\nOutcomes:\n\nThe primary outcome is pulmonary blood volume estimated to total blood volume ratio between patients with COPD and healthy controls individually matched for age, sex, and height.\n\nStatistical design:\n\nAll statistical analyses will be performed using R statistical software version 4.1.1 (R Project for Statistical Computing) within RStudio statistical software version 1.4.1717 (RStudio), and a two-tailed p\\\u003C0.05 will be considered statistically significant. Inspection of normality and variance homogeneity will be done by creating qq-plots and histogram.\n\nRegulatory considerations: This study will be submitted for approval by Regional Ethical Committee.\n\nPerspective: This study will help uncover fundamental aspects of the pathophysiology of COPD.",[94,95],"COPD (Chronic Obstructive Pulmonary Disease)","Healthy Subjects",[97,98,99,100,101],"TBV","PBV","COPD","Pulmonary blood volume","Total blood volume",{"date":34,"type":37},{"date":104,"type":37},"2025-09-15",{"date":106,"type":21},"2026-12-20",{"name":43,"class":44},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":77},"100535373","phase-3-new-treatment-of-cardiac-device-infections-immediate-reimplantation-after-removal-of-infected-system-100535373","NCT06250985","New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System","New Treatment of Cardiovascular Implantable Electronic Device (CIED) Infections; Immediate Reimplantation After Removal of Infected System","POET-PPM","Inclusion Criteria:\n\n* Culture positive or negative infection of a CIED acording to PI\n* Indication for removal of device\n* Clinical indication of device removal of existing device (concurrent left-sided IE is not a contraindication).\n* Indication for reimplantation of new device\n* A minimum of 3 days of sufficient antibiotic treatment (intravenous or oral) has been administered and\u002For culture negative antibiotic regimen have been adminstered until blood culture is examined.\n* stabilization criteria fulfilled i.e. I) negativ blood cultures, II) WBC \\\u003C 15 mia\u002FL or reduction of min. 25% and III) CRP \\\u003C50 or min. 25% reduction.\n\nExclusion Criteria:\n\n* Immunoincompetence (active chemotherapy or prednisone treatment \\> 20mg\u002Fday\n* Device-infection within last 6 months (relaps)\n* Septic shock\n* Stabilization criteria not fulfilled after 10 days of suficient antibiotic treatment","110 Years",{"count":118,"type":21},176,[120],"PHASE3","The goal of this randomized clinical trials is to ascertain the safety and efficacy of immediate reimplantation of cardiac electronic implantable devices in patients with endocarditis and device-infections, compared to standard care, i.e. reimplantation at a later procedure date.\n\nThe primary outcome is the occurence of the composite primary endpoint within 6 months of randomization consisting of\n\n* Death\n* Symptomatic embolism (systemic arterial embolism or pulmonary embolism)\n* Bacteremia og pocket-infection\n* Removal of a CIED due to new infection",[123],"Endocarditis, Bacterial","2026-09-28",{"date":73,"type":37},{"date":127,"type":37},"2024-04-29",{"date":129,"type":21},"2037-12-31",{"name":43,"class":44},""]